Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID‐19 Pandemic

Objective: We studied whether the use of hydroxychloroquine (HCQ) for COVID‐19 resulted in supply shortages for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods: We used US claims data (IQVIA PHARMETRICS® Plus for Academics [PHARMETRICS]) and hospital electroni...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Mercadé‐Besora, N, Guo, Y, Du, M, Li, X, Ramírez‐Anguita, JM, Moreno, A, Valente, A, Villalobos, F, Cheng, IL, Carrasco‐Ribelles, LA, van Swieten, MMH, Merkelbach, M, Magoya, M, Lasalvia, P, Pericàs‐Pulido, P, Berg, P, Bosco‐Lévy, P, Lillini, R, Ribeiro, R, Bagga, TK, Ramella, V, Khalid, S, Mayer, MA, Leis, A, Jödicke, AM, Burn, E, Prieto‐Alhambra, D, Català, M, Prats‐Uribe, A
Μορφή: Journal article
Γλώσσα:English
Έκδοση: Wiley 2024

Παρόμοια τεκμήρια